Ionis Pharmaceuticals said on Wednesday its experimental drug to treat a type of fatty liver disease met the main goal of reducing inflammation of the critical organ in a mid-stage trial.
Tag Archive for: metabolic dysfunction-associated steatohepatitis.
Akero Therapeutics’ drug to treat a type of fatty liver disease helped significantly reduce scarring after nearly two years in a study, it said on Monday, as the company targets a potential multi-billion-dollar market.
Boehringer Ingelheim on Monday revealed new Phase II data for its investigational GLP-1/glucagon receptor dual agonist survodutide, showing that it could elicit significant improvements in patients with metabolic dysfunction-associated steatohepatitis.